Clinical Trial

Clinical Performance of Laryseal Clear Versus Ambu Aura 40 Laryngeal Mask Airway for Preschool Children

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated April 30, 2026 (before its estimated June 25, 2026 completion). Its status may not reflect the trial's current state.
Summary
Preschool children have specific anatomical and physiological characteristics which necessitates careful selection of an appropriate airway management device. Supraglottic airway devices can be used in anticipated or unanticipated difficult airway providing continuous oxygenation and ventilation with less hemodynamic stress response and less postoperative complications. So alternative techniques such as SADs have gained prominence in pediatric anesthesia both as primary airway and as a conduit for endotracheal intubation. So this study will evaluate the clinical performance of Laryseal Clear and Ambu Aura40 laryngeal mask airway in preschool children undergoing surgical procedures.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-04-22.
Trial Details
NCT Number NCT07553247
Lead Sponsor Zagazig University
Conditions Supraglottic Airway Devices, Laryseal Clear Laryngeal Mask
Enrollment 54 participants
Start Date 2025-06-25
Primary Completion 2026-06-25 (estimated)
Study Completion 2026-07-01 (estimated)
Updated on ClinicalTrials.gov 2026-04-30